Glimepiride reduces CD14 expression and cytokine secretion from macrophages

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Ingham, Victoria ^a   Williams, Alun ^b   Bate, Clive ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; CD14 ANTIGEN; GLIMEPIRIDE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; PRION PEPTIDE 82-146; PRION PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIDIABETIC AGENT; CYTOKINE; GLIPIZIDE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE FRAGMENT; PRION; SULFONYLUREA DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MACROPHAGE; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; RAW 264 CELL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIA; HUMAN; KNOCKOUT MOUSE; METABOLISM; PRION; TIME;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD14; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; LIPOPOLYSACCHARIDES; MACROPHAGES; MEMBRANE MICRODOMAINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; NEUROGLIA; PEPTIDE FRAGMENTS; PRIONS; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 84902692007     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-115     Document Type: Article

References (70)

1. Schlachetzki JC, Hull M. Microglial activation in Alzheimer's disease. Curr Alzheimer Res 2009, 6(6):554-563.
2. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 1999, 154(6):1673-1684.
3. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong J-S, Zhang J. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19(6):533-542.
4. Combs CK, Karlo JC, Kao SC, Landreth GE. β-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001, 21(4):1179-1188.
5. Klegeris A, Walker DG, McGeer PL. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res 1997, 747(1):114-121.
6. Jin J, Shie FS, Liu J, Wang Y, Davis J, Schantz AM, Montine KS, Montine TJ, Zhang J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 2007, 4:2.
7. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002, 40:232-239.
8. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007, 7(2):161-167.
9. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12(9):1005-1015.
10. Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72(22):1899-1905.
11. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205(2):295-312.
12. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007, 28(5):639-647.
13. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000, 356(9242):1627-1631.
14. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 2003, 51:139-148.
15. Peyrin JM, Lasmezas CI, Haik S, Tagliavini F, Salmona M, Williams A, Richie D, Deslys JP, Dormont D. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 1999, 10(4):723-729.
16. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and Toll-like receptors 2 and 4 are required for fibrillar Ab-stimulated microglial activation. J Neurosci 2009, 29(38):11982-11992.
17. Thellung S, Corsaro A, Villa V, Venezia V, Nizzari M, Bisaglia M, Russo C, Schettini G, Aceto A, Florio T. Amino-terminally truncated prion protein PrP90-231 induces microglial activation in vitro. Ann N Y Acad Sci 2007, 1096:258-270.
18. Righi M, Mori L, Libero GD, Sironi M, Biondi A, Mantovani A, Donini SD, Ricciardi-Castagnoli P. Monokine production by microglial cell clones. Eur J Immunol 1989, 19(8):1443-1448.
19. Ranaivo HR, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM. Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006, 26(2):662-670.
20. Doens D, Fernandez P. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J Neuroinflammation 2014, 11(1):48.
21. Khoury JE, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to [beta]-amyloid fibrils. Nature 1996, 382(6593):716-719.
22. Calingasan NY, Erdely HA, Anthony Altar C. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 2002, 23(1):31-39.
23. Becher B, Fedorowicz V, Antel JP. Regulation of CD14 expression on human adult central nervous system-derived microglia. J Neurosci Res 1996, 45(4):375-381.
24. Bate C, Boshuizen R, Williams A. Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol 2005, 170(1-2):62-70.
25. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249(4975):1431-1433.
26. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002, 23(6):301-304.
27. Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci 2010, 30(46):15369-15373.
28. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988, 141(2):547-552.
29. Haziot A, Rong G, Bazil V, Silver J, Goyert S. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol 1994, 152(12):5868-5876.
30. Haziot A, Rong G, Lin X, Silver J, Goyert S. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995, 154(12):6529-6532.
31. Guo Nan Y, Hyejin J, Shinrye L, Ho Won L, Je-Yoel C, Kyoungho S. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 2009, 87(11):2578-2590.
32. Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract 1995, 28(Suppl):S147-S149.
33. Müller G, Dearey EA, Korndorfer A, Bandlow W. Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. J Cell Biol 1994, 126(5):1267-1276.
34. Müller G, Dearey EA, Punter J. The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3 T3 adipocytes. Biochem J 1993, 289(Pt 2):509-521.
35. Bate C, Tayebi M, Diomede L, Salmona M, Williams A. Glimepiride reduces the expression of PrPC, prevents PrPSc formation and protects against prion mediated neurotoxicity. PLoS One 2009, 4(12):e8221.
36. Moore KJ, Andersson LP, Ingalls RR, Monks BG, Li R, Arnaout MA, Golenbock DT, Freeman MW. Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol 2000, 165:4272-4280.
37. Stanton JD, Rashid MB, Mensa-Wilmot K. Cysteine-less glycosylphosphatidylinositol-specific phospholipase C is inhibited competitively by a thiol reagent: evidence for glyco-mimicry by p-chloromercuriphenylsulphonate. Biochem J 2002, 366(Pt 1):281-288.
38. Dürig J, Giese A, Schulz-Schaeffer W, Rosenthal C, Schmücker U, Bieschke J, Dührsen U, Kretzschmar HA. Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br J Haematol 2000, 108(3):488-495.
39. Duan W, Zhou J, Zhang S, Zhao K, Zhao L, Ogata K, Sakaue T, Mori A, Wei T. ESeroS-GS modulates lipopolysaccharide-induced macrophage activation by impairing the assembly of TLR-4 complexes in lipid rafts. Biochim Biophys Acta 2011, 1813(5):772-783.
40. Fernandez-Lizarbe S, Montesinos J, Guerri C. Ethanol induces TLR4/TLR2 association, triggering an inflammatory response in microglial cells. J Neurochem 2013, 126(2):261-273.
41. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RHN, Stricker B. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2007, 83(2):288-292.
42. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995, 92(20):9328-9332.
43. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 1997, 23(1-2):47-61.
44. McCoy M, Tansey M. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5(1):45.
45. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208(1):1-25.
46. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009, 34(1):163-177.
47. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-{alpha} triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 2010, 107(47):20518-20522.
48. Tobinick E, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008, 5(1):2.
49. Terreni L, De Simoni MG. Role of the brain in interleukin-6 modulation. Neuroimmunomodulation 1998, 5(3-4):214-219.
50. D'Arcangelo G, Tancredi V, Onofri F, D'Antuono M, Giovedi S, Benfenati F. Interleukin-6 inhibits neurotransmitter release and the spread of excitation in the rat cerebral cortex. Eur J Neurosci 2000, 12(4):1241-1252.
51. Tancredi V, D'Antuono M, Cafe C, Giovedi S, Bue MC, D'Arcangelo G, Onofri F, Benfenati F. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem 2000, 75(2):634-643.
52. Heine H, Ulmer AJ, El-Samalouti VT, Lentschat A, Hamann L. Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex. J Endotoxin Res 2001, 7(3):227-231.
53. Letiembre M, Hao W, Liu Y, Walter S, Mihaljevic I, Rivest S, Hartmann T, Fassbender K. Innate immune receptor expression in normal brain aging. Neuroscience 2007, 146(1):248-254.
54. Saltiel AR, Sherline P, Fox JA. Insulin-stimulated diacylglycerol production results from the hydrolysis of a novel phosphatidylinositol glycan. J Biol Chem 1987, 262(3):1116-1121.
55. Müller G, Jung C, Wied S, Welte S, Frick W. Insulin-mimetic signaling by the sulfonylurea glimepiride and phosphoinositolglycans involves distinct mechanisms for redistribution of lipid raft components. Biochemistry 2001, 40(48):14603-14620.
56. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996, 4(4):407-414.
57. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004, 378(Pt 2):281-292.
58. Mayor S, Rao M. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 2004, 5(4):231-240.
59. Lingwood D, Ries J, Schwille P, Simons K. Plasma membranes are poised for activation of raft phase coalescence at physiological temperature. Proc Natl Acad Sci U S A 2008, 105(29):10005-10010.
60. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010, 327(5961):46-50.
61. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006, 7(6):456-462.
62. Helms JB, Zurzolo C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic 2004, 5(4):247-254.
63. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002, 115(12):2603-2611.
64. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007, 20(6):947-956.
65. Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 2011, 8:92.
66. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008, 5:23.
67. Eisenberg S, Shvartsman DE, Ehrlich M, Henis YI. Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-Ras diffusion and signaling. Mol Cell Biol 2006, 26(19):7190-7200.
68. Gri G, Molon B, Manes S, Pozzan T, Viola A. The inner side of T cell lipid rafts. Immunol Lett 2004, 94(3):247-252.
69. Field KA, Holowka D, Baird B. Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling. Proc Natl Acad Sci U S A 1995, 92(20):9201-9205.
70. Hunter T. Signaling - 2000 and beyond. Cell 2000, 100(1):113-127.